Your browser doesn't support javascript.
Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera.
Yahalom-Ronen, Yfat; Erez, Noam; Fisher, Morly; Tamir, Hadas; Politi, Boaz; Achdout, Hagit; Melamed, Sharon; Glinert, Itai; Weiss, Shay; Cohen-Gihon, Inbar; Israeli, Ofir; Izak, Marina; Mandelboim, Michal; Caraco, Yoseph; Madar-Balakirski, Noa; Mechaly, Adva; Shinar, Eilat; Zichel, Ran; Cohen, Daniel; Beth-Din, Adi; Zvi, Anat; Marcus, Hadar; Israely, Tomer; Paran, Nir.
  • Yahalom-Ronen Y; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Erez N; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Fisher M; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Tamir H; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Politi B; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Achdout H; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Melamed S; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Glinert I; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Weiss S; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Cohen-Gihon I; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Israeli O; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Izak M; Magen David Adom, National Blood Services, Ramat Gan 52621, Israel.
  • Mandelboim M; Sheba Medical Center, Central Virology Laboratory, Ministry of Health, Tel Hashomer, Ramat Gan 52621, Israel.
  • Caraco Y; Hadassah Medical Center, Jerusalem 91120, Israel.
  • Madar-Balakirski N; Department of Pharmacology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Mechaly A; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Shinar E; Magen David Adom, National Blood Services, Ramat Gan 52621, Israel.
  • Zichel R; Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Cohen D; School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.
  • Beth-Din A; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Zvi A; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Marcus H; Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Israely T; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
  • Paran N; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Vaccines (Basel) ; 10(2)2022 Feb 14.
Article in English | MEDLINE | ID: covidwho-1699506
ABSTRACT
The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife® (rVSV-ΔG-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-ΔG-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants' mutations. We show that human sera from BriLife® vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife® vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife®-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10020291

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10020291